( NEW YORK--(BUSINESS WIRE)--Apr 19 2007...)ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting,Health

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonal antibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL) were the focus of 44 total presentations at the recently concluded 98th Annual Meeting of the American Association for Cancer Research (AACR), including seven oral presentations and 37 posters.

Important ERBITUX(R) (cetuximab) clinical data were the focus of two back-to-back oral presentations leading off the "Breakthroughs in Clinical Research" Plenary Session on April 16, 2007, which highlights the most important clinical studies presented at this prestigious meeting. The remaining presentations showcased ImClone's extensive research and development program with results from studies involving both ERBITUX, an IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), and multiple investigational monoclonal antibodies in the ImClone pipeline that target other critical cancer pathways.

Like ERBITUX, the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute to their overall therapeutic effects. These novel fully human antibodies, many of which are in early phase clinical testing, target cell surface receptors in various signaling pathways known or believed to play important roles in the growth and proliferation of tumors or tumor vasculature. Specific targets include insulin-like growth factor-1 receptor (IGF-1R), vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor alpha (PDGFR(alpha)), FMS-like tyrosine kinase 3 receptor (FLT3), fibroblast growth factor receptor 3 (FGFR3), among others.

"Our pipeline consists of a robust collection of IgG1 monoclonal antibodies targeted against cellular pathways that are emerging as cri
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
2. When Volume Matters, Immunoassay Systems Deliver
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. New Quality Control Systems for Every Laboratory Application
5. Immunoassay Systems - Your Laboratory Workhorse
6. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
7. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
8. NIEHS Researchers Identify Enzyme Critical in DNA Replication
9. Stanford Researchers Find Brain Pathway of Depression in Rats
10. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials